# Lineage Takes Delivery of Gene-edited Hypoimmune Cell Line Under Partnership With Factor Bioscience
Canonical URL: https://biopharmsignal.com/news/LCTX/lineage-takes-delivery-of-gene-edited-hypoimmune-cell-line-under-partnership-with-factor-bioscience
Ticker: LCTX
Company: Lineage Cell Therapeutics
Source: Lineage Cell Therapeutics
Published: 2026-01-06 13:00 EST
Original Source URL: https://investor.lineagecell.com
## Summary

CARLSBAD, Calif. --(BUSINESS WIRE)--Jan. 6, 2026-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf,” cell therapies for serious medical conditions, today announced the receipt of a novel, induced

## Article Body
CARLSBAD, Calif. --(BUSINESS WIRE)--Jan. 6, 2026-- Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel allogeneic, or “off the shelf,” cell therapies for serious medical conditions, today announced the receipt of a novel, induced
## Recent Company News
- 2026-05-12 20:01 EST — [Lineage Cell Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update](https://biopharmsignal.com/news/LCTX/lineage-cell-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-update) — Source: Lineage Cell Therapeutics
- 2026-05-05 12:00 EST — [Lineage Cell Therapeutics to Report First Quarter 2026 Financial Results and Provide Business Update on May 12, 2026](https://biopharmsignal.com/news/LCTX/lineage-cell-therapeutics-to-report-first-quarter-2026-financial-results-and-provide-business-update-on-may-12-2026) — Source: Lineage Cell Therapeutics
- 2026-05-04 12:00 EST — [OpRegen® 3 Year Results in Patients With GA Presented at Foundation Fighting Blindness Retinal Innovation Summit 2026](https://biopharmsignal.com/news/LCTX/opregenr-3-year-results-in-patients-with-ga-presented-at-foundation-fighting-blindness-retinal-innovation-summit-2026) — Source: Lineage Cell Therapeutics
- 2026-04-13 12:00 EST — [Lineage Announces Formation of Scientific Advisory Board](https://biopharmsignal.com/news/LCTX/lineage-announces-formation-of-scientific-advisory-board) — Source: Lineage Cell Therapeutics
- 2026-03-24 12:00 EST — [Lineage Launches New Cell Therapy Program in Corneal Endothelial Disease](https://biopharmsignal.com/news/LCTX/lineage-launches-new-cell-therapy-program-in-corneal-endothelial-disease) — Source: Lineage Cell Therapeutics
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)